Eurofins Scientific SE
PAR:ERF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Eurofins Scientific SE
PAR:ERF
|
LU |
|
R
|
Royal Caribbean Cruises Ltd
BMV:RCL
|
US |
|
Veritone Inc
NASDAQ:VERI
|
US |
|
Daiki Aluminium Industry Co Ltd
TSE:5702
|
JP |
|
D
|
Diageo PLC
PAR:DGE
|
UK |
|
A
|
Assertio Holdings Inc
NASDAQ:ASRT
|
US |
|
FibroGen Inc
NASDAQ:FGEN
|
US |
|
Tate & Lyle PLC
LSE:TATE
|
UK |
|
Prima Alloy Steel Universal Tbk PT
IDX:PRAS
|
ID |
|
LHN Ltd
SGX:41O
|
SG |
|
InspireMD Inc
NASDAQ:NSPR
|
IL |
|
Tourmaline Bio Inc
NASDAQ:TRML
|
US |
|
Oceania Healthcare Ltd
ASX:OCA
|
NZ |
Wall St Price Targets
ERF Price Targets Summary
Eurofins Scientific SE
According to Wall Street analysts, the average 1-year price target for ERF is 71.59 EUR with a low forecast of 48.48 EUR and a high forecast of 90.3 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is ERF's stock price target?
Price Target
71.59
EUR
According to Wall Street analysts, the average 1-year price target for ERF is 71.59 EUR with a low forecast of 48.48 EUR and a high forecast of 90.3 EUR.
What is the Revenue forecast for Eurofins Scientific SE?
Projected CAGR
7%
Over the last 14 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 5 years is 7%.
What is the Operating Income forecast for Eurofins Scientific SE?
Projected CAGR
19%
Over the last 14 years, the compound annual growth rate for Operating Income has been 15%. The projected CAGR for the next 5 years is 19%.
What is the Net Income forecast for Eurofins Scientific SE?
Projected CAGR
26%
Over the last 14 years, the compound annual growth rate for Net Income has been 17%. The projected CAGR for the next 5 years is 26%.
